HSIC Henry Schein
Mature distributor with stuck margins and flat revenue — value trap at current price.
The story
Henry Schein is a mature healthcare distributor (dental, medical, animal health) with limited organic growth, thin distribution margins around 5%, and modest scale advantages. Revenue has been essentially flat-to-slightly-growing, and despite repeated margin recovery narratives, operating margins remain stuck near 5%. The business is in late maturity with no credible path to structurally higher margins or accelerated growth.
Keeping prior drivers essentially unchanged — TTM revenue growth of ~3% and margins at 5.2% confirm the prior thesis of a low-growth, thin-margin distributor. Nudging target margin from 6% to 5.8% reflects that after multiple years of margin compression with no recovery, even 6% looks optimistic; terminal growth stays at 2.5%, well below the 4.81% risk-free rate. Sales-to-capital of 2.1 matches the observed 2.14, and beta of 1.0 is reasonable for a levered distributor.
Value drivers
| Revenue growth (Y1) | 2.5% |
| Terminal growth | 2.5% |
| Forecast horizon | 7y |
| Target operating margin | 5.8% |
| Years to target margin | 7 |
| Sales-to-capital | 2.10 |
| Beta | 1.00 |
| Failure probability | 2.5% |
| Cost of capital (WACC) | 8.6% |
| Terminal WACC | 8.6% |
Valuation bridge
| PV of explicit FCFF | 2.34B |
| PV of terminal value | 4.83B |
| Equity value | 2.04B |
| ÷ shares → per share | $17.91 |
News
neutral +0.10 · 8 articles
- Henry Schein (HSIC) is an Incredible Growth Stock: 3 Reasons Why
- Why Is Henry Schein (HSIC) Up 0.9% Since Last Earnings Report?
- Is Henry Schein (HSIC) Stock Undervalued Right Now?
- Henry Schein (HSIC) Looks Modestly Undervalued, Is More Upside Still Available?
- Growth Trajectory and Attractive Valuations Support Henry Schein’s (HSIC) Bullish Thesis
- HSIC vs. SAUHY: Which Stock Is the Better Value Option?
- What Are Wall Street Analysts' Target Price for Henry Schein Stock?
- Is HSIC Worth Buying as Growth Improves but Execution Risks Persist?
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 13.94B | 2.5% | 5.3% | 566.55M | 161.93M | 404.62M | 372.72M |
| 2 | 14.29B | 2.5% | 5.4% | 589.41M | 165.98M | 423.44M | 359.30M |
| 3 | 14.65B | 2.5% | 5.5% | 613.07M | 170.13M | 442.94M | 346.22M |
| 4 | 15.01B | 2.5% | 5.6% | 637.53M | 174.38M | 463.15M | 333.48M |
| 5 | 15.39B | 2.5% | 5.6% | 662.84M | 178.74M | 484.10M | 321.09M |
| 6 | 15.77B | 2.5% | 5.7% | 689.02M | 183.21M | 505.81M | 309.04M |
| 7 | 16.17B | 2.5% | 5.8% | 716.09M | 187.79M | 528.30M | 297.33M |
Key risks
- Continued margin pressure from consolidating dental/medical group purchasing organizations
- Revenue stagnation as dental practice economics remain challenging
- Net debt of ~$3B limiting financial flexibility and increasing downside risk
Catalysts
- Acquisitions boosting revenue scale and synergies
- Dental market recovery driving volume improvement
- Cost optimization initiatives finally gaining traction